Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tianjin Anding Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07356765CT.gov Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms | — | Enrolling By Invitation | — | — | — |
NCT07359209CT.gov Berberine Improving Cognitive Impairments in Schizophrenia | — | Enrolling By Invitation | — | — | — |
NCT03708549CT.gov Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients | — | Unknown | — | — | — |
NCT02983188CT.gov Berberine as Adjuvant Treatment for Schizophrenia Patients | — | Completed | — | — | — |
NCT03251716CT.gov Berberine Treat Metabolic Syndrome in Schizophrenia | — | Completed | — | — | — |
NCT03548155CT.gov Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia | — | Completed | — | — | — |
NCT02936414CT.gov Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Umbellatine (this asset) | Tianjin Anding Hospital | Approved | B · 60 |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Iloperidone | Vanda Pharmaceuticals | P4 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Umbellatine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Inherited Lipid Metabolism Disorder | — | P4 | BBB · 72 |
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BB · 69 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Umbellatine in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/umbellatine-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →